BioPharma Resources

Investigational drug · Phase 3

Giredestrant

Also called: RO7197597, GDC-9545, RG6171

Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

16

15 still active

All registered trials

30

Any phase or sponsor naming "Giredestrant"

First trial start

2018

Mar 30, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Giredestrant", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Early Breast Cancer
  • Breast Cancer
  • Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
  • Metastatic Breast Cancer
  • Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
  • Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
  • Ovarian Cancer
  • Estrogen Receptor-Positive Breast Cancer
  • HER2-Negative Breast Cancer
  • Locally Advanced or Metastatic Breast Cancer

Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Oncology · Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "Giredestrant" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 34 on PubMed

Also in development for Early Breast Cancer

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • LHRH AgonistPhase 36 trials

    Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

  • Fixed of PertuzumabPhase 31 trial

    Roche (Genentech) · Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.